ArticleThe Journal of veterinary medical science2026
Cisplatin-induced acute kidney injury in lupus-prone NZB/W F1 mice: a potential experimental model of acute kidney injury superimposed on chronic kidney disease.
Article in The Journal of veterinary medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease frequently complicated by immune complex-mediated glomerulonephritis that can progress to chronic kidney disease (CKD). Acute kidney injury (AKI) superimposed on CKD (AKI on CKD) is associated with a markedly poor prognosis; however, experimental models that accurately reflect this condition in SLE are limited. This study aimed to establish and characterize an AKI on CKD model using SLE-prone mice with pre-existing immune complex-mediated glomerulonephritis. Female NZB/W F1 mice with established glomerulonephritis at 32 weeks of age were administered cisplatin (10 mg/kg, intraperitoneally) to induce AKI. Blood urea nitrogen (BUN), serum neutrophil gelatinase-associated lipocalin (NGAL), urinary NGAL, and the urinary NGAL-to-creatinine ratio were evaluated as clinicopathological indicators of renal injury. Following cisplatin administration, BUN and serum NGAL concentrations increased significantly. Urinary NGAL concentrations and the urinary NGAL-to-creatinine ratio were also significantly elevated on days 1-4 after AKI induction compared with baseline, whereas urinary protein concentration, urinary creatinine concentration, and the urinary protein-to-creatinine ratio showed no significant changes. NGAL is synthesized by macrophages, glial cells, and epithelial cells under inflammatory conditions and is an established biomarker of tubular injury in AKI. The observed increases in BUN and NGAL parameters confirm successful induction of AKI in SLE mice with pre-existing CKD. This cisplatin-induced AKI model in NZB/W F1 mice may serve as a useful AKI on CKD model for investigating disease mechanisms and developing therapeutic strategies for AKI in patients with SLE and CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.